Cancer treatment and atrial fibrillation: use of pharmacovigilance databases to detect cardiotoxicity

Kalliopi Keramida¹, Gerasimos Filippatos¹, Dimitrios Farmakis^{1

2}

Affiliations

¹ Cardio-oncology Clinic, Heart Failure Unit, Department of Cardiology, National and Kapodistrian University of Athens Medical School, Athens University Hospital Attikon, Athens, Greece.
² University of Cyprus Medical School, Nicosia, Cyprus.

Editorial

Kalliopi Keramida et al. Eur Heart J Cardiovasc Pharmacother. 2021.

. 2021 Jul 23;7(4):321-323.

doi: 10.1093/ehjcvp/pvaa059.

Kalliopi Keramida¹, Gerasimos Filippatos¹, Dimitrios Farmakis^{1

2}

¹ Cardio-oncology Clinic, Heart Failure Unit, Department of Cardiology, National and Kapodistrian University of Athens Medical School, Athens University Hospital Attikon, Athens, Greece.
² University of Cyprus Medical School, Nicosia, Cyprus.

No abstract available

Comment on

Identification of anticancer drugs associated with atrial fibrillation: analysis of the WHO pharmacovigilance database.
Alexandre J, Salem JE, Moslehi J, Sassier M, Ropert C, Cautela J, Thuny F, Ederhy S, Cohen A, Damaj G, Vilque JP, Plane AF, Legallois D, Champ-Rigot L, Milliez P, Funck-Brentano C, Dolladille C. Alexandre J, et al. Eur Heart J Cardiovasc Pharmacother. 2021 Jul 23;7(4):312-320. doi: 10.1093/ehjcvp/pvaa037. Eur Heart J Cardiovasc Pharmacother. 2021. PMID: 32353110